Connect with us

Health

92% of LGBTQ+ adults have received at least one dose for COVID-19

59% of LGBTQ+ respondents reported Covid-19 made them feel socially isolated, & 50% reported that it impacted their mental health.

Published

on

Photo Credit: County of Los Angeles

NEW YORK – A summary of data collected as part of the annual LGBTQ+ Community Survey by the Human Rights Campaign Foundation in partnership and supported by The Rockefeller Foundation in New York City, found that the vast majority – 92% – of LGBTQ+ adults surveyed in the United States had received at least one vaccination for Covid-19.

Although vaccination rates vary somewhat within the LGBTQ+ community, the rates across race and ethnicity, gender identity and sexual orientation, and age are well above the rates for various general adult populations where the data are available:

  • By race and ethnicity, 90% of Latinx respondents, 85% of Black respondents, 96% of Asian or Pacific Islander respondents, and 85% of Native American/Alaskan and Middle Eastern/North African LGBTQ+ adults, among other race identities have received at least one dose of a Covid-19 vaccine.
  • By gender identity and sexual orientation, 92% of cisgender lesbian and bi+ women, 93% of cisgender gay and bi+ men, and 92% of transgender and non-binary people have received at least one dose of a Covid-19 vaccine.
  • By age, 91% of LGBTQ+ respondents aged 18-34, 92% of LGBTQ+ respondents aged 35-5, and 94% of LGBTQ+ respondents aged 55 and older have received at least one dose of a Covid-19 vaccine

While vaccination rates are high, Covid-19 took a toll on well-being among respondents. The survey finds that 59% of LGBTQ+ respondents reported that Covid-19 made them feel socially isolated, and 50% of respondents reported that it impacted their mental health.

“Increasing vaccination rates among communities of color is a major focus for us, and working with the Human Rights Campaign Foundation gives us the opportunity to better understand the impact of Covid-19 on LGBTQ communities of color. We look forward to continuing our support and outreach.” said Otis Rolley, Senior Vice President of Equity and Economic Opportunity at The Rockefeller Foundation.

Photo Credit: County of Los Angeles

The data finds the Covid-19 pandemic led to social and financial loss, especially among LGBTQ+ people of color:

  • 21% of LGBTQ+ adults surveyed reported that a close family member or friend has died from Covid-19
  • LGBTQ+ people of color surveyed reported higher levels of loss due to Covid-19 compared to white LGBTQ+ people:
    • 30% of Latinx LGBTQ+ respondents
    • 28% of Black LGBTQ+ respondents
    • 25% of Native American/Alaskan and Middle Eastern/North African LGBTQ+ respondents, among other race identities
    • 18% of Asian/Pacific Islander LGBTQ+ respondents
    • 17% of white LGBTQ+ respondents
  • 36% of LGBTQ+ respondents reported that a close friend or family member has become very sick from Covid-19
  • 24% of LGBTQ+ respondents reported that Covid-19 has negatively impacted their financial well-being
  • LGBTQ+ people of color surveyed are more likely than white LGBTQ+ people to have experienced a negative financial impact during the pandemic:
    • 33% of Native American/Alaskan and Middle Eastern/North African LGBTQ+ adults, among other race identities
    • 26% of Asian/Pacific Islander LGBTQ+ adults
    • 26% of Latinx LGBTQ+ adults
    • 25% of Black LGBTQ+ adults
    • 22% of white LGBTQ+ adults

“There are many reasons why LGBTQ+ vaccination rates may be higher than the general population, including higher percentages of the LGBTQ+ community being liberal, living in blue states, and living in urban areas,” said CMI Senior Director of Research, David Paisley. “While participants had strong education levels, those with no more than a high school diploma still had an 87% vaccination rate. We also see that Covid isolation significantly impacted LGBTQ+ people, which may have motivated quick vaccination to reenter the community.”

The new data build on the HRC Foundation’s previously released reports, including the most recent report, “Covid-19 and the LGBTQ Community: Vaccinations and the Economic Toll of the Pandemic,” which was released as a part of the HRC Foundation’s vaccine public education campaign: “For Ourselves, For Each Other: Getting to the Other Side of the Pandemic.” The HRC Foundation has also partnered with the Black Trans Advocacy Coalition on a resource, “Finding Financial Stability During Turbulent Times,” with steps and advice for those who may be struggling to make ends meet during these difficult times. Read more about the HRC Foundation’s efforts during Covid-19 here.

The Rockefeller Foundation is supporting the Human Rights Campaign Foundation on a number of Covid-19-related projects to support research and community education to reach LGBTQ communities of color during this crisis through The Rockefeller Foundation’s Equity-First Vaccination Initiative. Learn more here.

Continue Reading
Advertisement

Health

CDC & World Health Org issue warning to gay/bi men over monkeypox

Chance of exposure to monkeypox right now doesn’t mean the risk is limited only to the gay and bisexual community

Published

on

CDC Headquarters in Atlanta, Georgia (US Government/CDC)

ATLANTA – Health officials on both sides of the Atlantic are cautioning gay and bisexual men to be cautious as numbers of infections of the non-lethal monkeypox continue to climb. The outbreak according to the World Health Organization can be traced to sexual activity stemming from LGBTQ+ events, one in the Spanish in the Canary Islands and the other in Belgium.

The chairman of the World Health Organization Emergency Committee, Professor David L. Heymann told reporters that WHO researchers determined that cases were confirmed stemming from an LGBTQ+ Pride celebration in the Canary Islands that drew tens of thousands of revelers and linked to the Darklands Festival, a large-scale fetish festival in the port city of Antwerp, Belgium.

“We know monkeypox can spread when there is close contact with the lesions of someone who is infected,” Heymann said. “And it looks like the sexual contact has now amplified that transmission.”

“It’s very possible there was somebody who got infected, developed lesions on the genitals, hands or somewhere else, and then spread it to others when there was sexual or close, physical contact,” Heymann added. “And then there were these international events that seeded the outbreak around the world, into the US and other European countries.”

A section of skin tissue, harvested from a lesion on the skin of a monkey, that had been infected with monkeypox virus, is seen at 50X magnification on day four of rash development in 1968. (CDC/Reuters)

On Monday, Dr. John Brooks, an official with the U.S. Centers for Disease Control and Prevention in Atlanta told reporters that anyone can contract monkeypox through close personal contact regardless of sexual orientation. He added that so far many of the people affected globally are men who identify as gay or bisexual. Though they may have greater chance of exposure to monkeypox right now, that doesn’t mean the risk is limited only to the gay and bisexual community, he said.

The United Nations’ AIDS agency (UNAID) in a press release Monday decried the semingly homophobic news coverage of the recent outbreaks of monkeypox in Europe and the United States.

“Lessons from the AIDS response show that stigma and blame directed at certain groups of people can rapidly undermine outbreak response,” UNAIDS said.

Monkeypox is not usually fatal but often manifests itself through fever, muscle aches, swollen lymph nodes, chills, exhaustion and a chickenpox-like rash on the hands and face.

The virus can be transmitted through contact with skin lesions or droplets of bodily fluid from an infected person. Most people recover from the disease within several weeks without requiring hospitalization. Vaccines against smallpox, a related disease, are also effective in preventing monkeypox and some antiviral drugs are being developed.

University of Maryland’s Vice President and Chief of Infectious Diseases at University of Maryland Upper Chesapeake Health Center, Dr. Faheem Younus, tweeted a note of reassurance Monday; “Monkeypox cases are concerning but the risk of this becoming a COVID like pandemic is ZERO%”

Continue Reading

AIDS and HIV

U.S. announces more funding for HIV/AIDS fight in Latin America

Jill Biden made announcement on Saturday in Panama

Published

on

Former Panamanian first lady Lorena Castillo and UNAIDS in 2017 launched a campaign to fight discrimination against Panamanians with HIV/AIDS. Panama will receive $12.2 million in new PEPFAR funding to further combat the HIV/AIDS epidemic in Latin America. (Washington Blade photo by Michael K. Lavers)

PANAMA CITY — First lady Jill Biden on Saturday announced the U.S. will provide an additional $80.9 million to the fight against HIV/AIDS in Latin America.

Biden during a visit to Casa Hogar el Buen Samaritano, a shelter for people with HIV/AIDS in Panama City, said the State Department will earmark an additional $80.9 million for President’s Emergency Plan for AIDS Relief-funded work in Latin America. A Panamanian activist with whom the Washington Blade spoke said LGBTQ+ people were among those who met with the first lady during her visit.

Pope Francis visited the shelter in 2019.

“I’m glad we have the opportunity to talk about how the United States and Panama can work together to combat HIV,” said the first lady.

Michael LaRosa, the first lady’s spokesperson, noted Panama will receive $12.2 million of the $80.9 million in PEPFAR funding.

“This funding, pending Congressional notification, will support expanded HIV/AIDS services and treatment,” said LaRosa.

UNAIDS statistics indicate an estimated 31,000 Panamanians were living with HIV/AIDS in 2020. The first lady’s office notes the country in 2020 had the highest number of “newly notificated cases of HIV/AIDS” in Central America.

The first lady visited Panama as part of a trip that included stops in Ecuador and Costa Rica.

The Summit of the Americas will take place next month in Los Angeles. The U.S. Agency for International Development and PEPFAR in April announced they delivered more than 18 million doses of antiretroviral drugs for Ukrainians with HIV/AIDS.

Continue Reading

Health

FDA oks adverts for first condom specifically designed for anal intercourse

FDA authorized One Male Condom also aa a contraceptive to reduce risk of pregnancy and the transmission of STIs during vaginal intercourse

Published

on

Courtesy of Global Protection Corp.

WASHINGTON – Boston, Massachusetts-based Global Protection Corporation, a world leader in manufacturing and distributing sexual health products, condom manufacturing, lubricant manufacturing and much more was granted permission by the U.S. Food and Drug Administration, (FDA), to market its condoms designed for anal intercourse.

On Wednesday, the FDA authorized the marketing of the One Male Condom, are also indicated as a contraceptive to help reduce the risk of pregnancy and the transmission of STIs during vaginal intercourse.

Before today’s authorization, the FDA had not cleared or approved condoms specifically indicated for anal intercourse. Unprotected anal intercourse carries the greatest sexual exposure risk of HIV transmission. Consistent and correct condom use has the potential to significantly help decrease the risk of STIs. While today’s authorization underscores the public health importance of condoms tested and labeled specifically for anal intercourse, all other FDA-cleared condoms can continue to be used for contraception and STI prevention. It’s important to continue to use condoms consistently and correctly to reduce the risk of STI transmission, including HIV, and to prevent pregnancy.

“The risk of STI transmission during anal intercourse is significantly higher than during vaginal intercourse. The FDA’s authorization of a condom that is specifically indicated, evaluated and labeled for anal intercourse may improve the likelihood of condom use during anal intercourse,” said Courtney Lias, Ph.D., director of the FDA’s Office of GastroRenal, ObGyn, General Hospital, and Urology Devices in the Center for Devices and Radiological Health.

“Furthermore, this authorization helps us accomplish our priority to advance health equity through the development of safe and effective products that meet the needs of diverse populations. This De Novo authorization will also allow subsequent devices of the same type and intended use to come to the market through the 510k pathway, which could enable the devices to get on the market faster,” she added.

The One Male Condom is a natural rubber latex sheath that covers the penis. It has three different versions: standard, thin and fitted. The fitted condoms, available in 54 different sizes, incorporate a paper template to aid in finding the best condom size for each user. When used during anal intercourse, the One Male Condom should be used with a condom-compatible lubricant.

The safety and efficacy of the One Male Condom was studied in a clinical trial comprised of 252 men who have sex with men and 252 men who have sex with women. All participants were between 18 through 54 years old.  

The study found that the total condom failure rate was 0.68% for anal intercourse and 1.89% for vaginal intercourse with the One Male Condom. Condom failure rate was defined as the number of slippage, breakage or both slippage and breakage events that occurred over the total number of sex acts performed.

For the One Male Condom, the overall percentage of adverse events was 1.92%. Adverse events reported during the clinical trial included symptomatic STI or recent STI diagnosis (0.64%), condom or lubricant-related discomfort (0.85%), partner discomfort with lubricant (0.21%) and partner urinary tract infection (0.21%).

The symptomatic STI or recent STI diagnoses observed in the study were self-reported and may be the result of subjects having intercourse without a condom or may have preceded use of the One Male Condom, as STIs were not measured at baseline.

The FDA reviewed the One Male Condom through the De Novo premarket review pathway, a regulatory pathway for low- to moderate-risk devices of a new type. Along with this De Novo authorization, the FDA is establishing criteria called special controls that define the requirements related to labeling and performance testing.

When met, the special controls, in combination with general controls, provide a reasonable assurance of safety and effectiveness for devices of this type. This action also creates a new regulatory classification, which means that subsequent devices of the same type with the same intended use may go through the FDA’s 510(k) pathway, whereby devices can obtain clearance by demonstrating substantial equivalence to a predicate device.

The FDA granted the marketing authorization to Global Protection Corp.

Continue Reading
Advertisement
Advertisement

Follow Us @LosAngelesBlade

Sign Up for Blade eBlasts

Popular